ROCKVILLE, Md., March 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy...
Hence then, the article about regenxbio announces presentations at the 2025 muscular dystrophy association mda clinical scientific conference was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference )
Also on site :
- Olympic Gymnastics Legend, Who Scored the World’s First Perfect 10, Relives Her Greatest Performance 50 Years Later
- Princess Diana's Alleged Camilla Face-Off Over King Charles Happened Here—Now the London Estate Is Listed for $33 Million
- Drew Barrymore's Buttercream-Yellow Walmart Kitchen Collection Is the Summery Refresh Your Space Needs